These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 2158396)

  • 1. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
    Utsugi T; Mattern MR; Mirabelli CK; Hanna N
    Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
    Baloch Z; Cohen S; Coffman FD
    J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.
    Utsugi T; Demuth S; Hanna N
    Cancer Res; 1989 Mar; 49(6):1429-33. PubMed ID: 2538225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
    Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
    Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
    Epstein RJ; Smith PJ
    Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.
    Mattern MR; Mong SM; Bartus HF; Mirabelli CK; Crooke ST; Johnson RK
    Cancer Res; 1987 Apr; 47(7):1793-8. PubMed ID: 3028614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
    Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
    Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
    Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
    Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.
    Alexander RB; Nelson WG; Coffey DS
    Cancer Res; 1987 May; 47(9):2403-6. PubMed ID: 2436763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
    Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
    Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity mediated by tumor necrosis factor in variant subclones of the ME-180 cervical carcinoma line: modulation by specific inhibitors of DNA topoisomerase II.
    Coffman FD; Green LM; Godwin A; Ware CF
    J Cell Biochem; 1989 Feb; 39(2):95-105. PubMed ID: 2541144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells.
    Cimoli G; Valenti M; Venturini M; Conte P; Russo P
    Anticancer Res; 1992; 12(5):1411-4. PubMed ID: 1444198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
    Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
    Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.